Drugs / Phenelzine
Phenelzine
also known as
phenelzine sulfate · Fenelzina · Nardil · NSC-170957 · Phenelzine acid sulfate · Phenelzine sulphate
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | NARDIL | — | 1961-06-09 | fda.gov ↗ |
Trials 5
196019611962196319641965196619671968196919701971197219731974197519761977197819791980198119821983198419851986198719881989199019911992199319941995199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028202920302031
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT04978298 | Jul 2021 → Feb 2023 | — | Celgene Corporation | Completed | No outcome recorded |
| Phase 1 | NCT03505528 | Aug 2017 → Oct 2019 | breast cancer | EpiAxis Therapeutics | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT02217709 | Sep 2014 → Jun 2020 | prostate adenocarcinoma | University of Southern California | Completed | No outcome recorded |
| Phase 2 | NCT01253642 | Jul 2010 → Sep 2016 | hormone-resistant prostate carcinoma, prostate adenocarcinoma | OHSU Knight Cancer Institute | Terminated | No outcome recorded Stop: Enrollment |
| Phase 41 trial | ||||||
| Phase 4 | NCT06580041 | Nov 2024 → Sep 2029 expected | major depressive disorder | University of California, San Francisco | Enrolling by invitation | No outcome recorded |
| Comparator or background therapy4 trials | ||||||
| Phase 1 | NCT03979820 Comparator | Jul 2019 → Apr 2020 | — | Boehringer Ingelheim | Terminated | No outcome recorded |
| Phase 1 | NCT03694119 Comparator | Jul 2018 → Jan 2019 | — | Celgene Corporation | Completed | No outcome recorded |
| Phase 1/2 | NCT00612807 Background | Jul 2006 → Jun 2010 | major depressive disorder | Duke University | Completed | No outcome recorded |
| — | NCT01944657 Comparator | Sep 2013 → Dec 2015 | major depressive disorder | Sheppard Pratt Health System | Withdrawn | No outcome recorded Stop: Enrollment |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Phenelzine | “MAOI (daily dose of at least 30 mg tranylcypromine or 45 mg of phenelzine)” NCT00612807 ↗7“phenelzine (Nardil)” NCT01944657 ↗ |
| Known as | Fenelzina | ChEMBL registry synonym — accepted as the source's own label CHEMBL1089 ↗ |
| Known as | Nardil | “phenelzine (Nardil)” NCT01944657 ↗ |
| Known as | NSC-170957 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1089 ↗ |
| Known as | Phenelzine acid sulfate | ChEMBL registry synonym — accepted as the source's own label CHEMBL1089 ↗ |
| Known as | phenelzine sulfate | “This phase 1b study will determine the safety and efficacy of combined treatment of Abraxane and phenelzine sulfate (Nardil) for metastatic or locally advanced breast cancer.” NCT03505528 ↗ |
| Known as | Phenelzine sulphate | ChEMBL registry synonym — accepted as the source's own label CHEMBL1089 ↗ |
| Action | Inhibit | “Phenelzine sulfate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.” NCT01253642 ↗ |
| Modality | Small molecule | — CHEMBL1089 ↗ |
| Route | Oral | “Given PO” NCT01253642 ↗ |